Drug intelligence / Profile preview

ASKG322

Development stage: Unknown
Lead developer: AskGene Pharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

**ASKG322** is an investigational AskGene Pharma fusion-protein program listed for oncology. Public drug-database records describe it as an interleukin-2 inhibitor developed using AskGene's SmartKine cytokine-prodrug platform, with reported Phase 1 development for neoplasms including solid tumors. Its precise molecular composition, IL-2 binding architecture, administration route, and formulation have not been publicly characterized in accessible primary sources.

Other names: ASKG 322ASKG322ASKG-322

Targets

IL-2 (Interleukin 2)

Beyond the preview

Go deeper on ASKG322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASKG322.

Explore the full profile